Becker's Hospital Review

64 CIO / HEALTH IT Symantec: A hacking group is targeting the health sector to steal intellectual property — 6 things to know By Julie Spitzer S ymantec identified a hacker group known as Orangeworm that is break- ing into U.S. healthcare organizations' X-Ray, MRI and other medical machines as part of an ongoing corporate espionage op- eration, according to a Symantec report re- leased April 23. Here are six things to know. 1. Orangeworm was a previously unknown group that Symantec discovered in 2015. It installs a custom backdoor called "Trojan. Kwampirs" in the networks of large interna- tional corporations in healthcare sector pri- marily in the U.S. but also in Europe and Asia. 2. According to the report, the known victims include healthcare providers, drugmakers, IT solution providers for healthcare and equip- ment manufacturers serving the healthcare industry, most likely in pursuit of corporate espionage. 3. Orangeworm's secondary targets include the manufacturing, IT, agriculture and logis- tics industries. 4. Trojan.Kwampirs is a backdoor Trojan that allows the attackers remote access to the com- promised computer. Kwampirs "decrypts and extracts a copy of its main DLL payload from its resource section. Before writing the pay- load to disk, it inserts a randomly generated string into the middle of the decrypted pay- load in an attempt to evade hash-based detec- tions," the report states. 5. Aer hackers have infected a computer with the Kwampirs malware, "the attackers have the ability to extend the malware's func- tionality by downloading and executing ad- ditional modules in memory," Alan Neville, a Symantec researcher, told Forbes. "ese modules may be customized to the victim's environment to assist the attackers in performing any desirable action on these devices." 6. Symantec does not believe Orangeworm is a state-sponsored actor but rather thinks it is an individual or a small group of indi- viduals. Symantec noted there are no tech- nical or operational indicators to determine the group's origin. n Teladoc sees revenue jump 109%, but posts net loss of $23.9M: 5 things to know By Julie Spitzer T eladoc posted $89.6 million in revenue in its first quarter ended March 31, which is up 109 percent from the same period in 2017, accord- ing to first quarter 2018 fiscal year earnings results posted May 1. Here are five things to know. 1. Teladoc reported 553,730 visits from paid U.S. members, a 44 percent increase from one year prior. 2. The company's paid U.S. memberships also in- creased 41 percent to 20.8 million. 3. Teladoc reported a $62.8 million gross profit, which was 70 percent of its total revenue. 4. However, it noted a net loss of $23.9 million, com- pared to $15.7 million in the same period in 2017. 5. Net loss per basic and diluted share was $0.39 for first quarter 2018, compared to a net loss per share of $0.30 one year prior. Teladoc expects revenue in the range of $86 million to $87 million for its second quarter, and it expects a net loss per share, based on 62.6 million weighted average outstanding shares, to be between $0.35 and $0.37. n St. Jude launches public pediatric cancer genomics platform on the cloud By Jessica Kim Cohen M emphis, Tenn.-based St. Jude Children's Research Hospital launched St. Jude Cloud, an online da- ta-sharing platform for pediatric cancer researchers, April 12. St. Jude Cloud, which hospital officials said is the largest public repository of pediatric cancer genomics data, offers research- ers access to whole-genome sequencing, whole-exome se- quencing and RNA sequencing datasets from more than 5,000 pediatric cancer patients and survivors. Researchers also have the option to upload and analyze in- dependent datasets with St. Jude Cloud's bioinformatics and data visualization tools on the cloud-based platform. St. Jude officials expect to host 10,000 whole-genome se- quences on St. Jude Cloud by 2019. The genomic datasets available on St. Jude Cloud are stored in Azure, Microsoft's cloud computing service, and managed by DNAnexus, a Mountain View, Calif.-based biomedical informatics platform. "Sharing research and scientific discoveries is vital to advanc- ing cures and saving lives, especially in rare diseases like pedi- atric cancer," said James R. Downing, MD, president and CEO at St. Jude. "St. Jude Cloud offers researchers access to ge- nomics data and analysis tools that will drive faster progress toward cures for catastrophic diseases of childhood." n

• Cover